Founded in 2013, Brevitest Technologies is a life sciences company focused on improving patient care. While most traditional tests require sending samples to an outside lab and waiting days to receive results, Brevitest technologies has developed a biomedical device capable of performing these same tests in a point-of-care setting. Brevitest’s patented biomedical assay platform technology performs traditional quantitative ELISAs in an automated fashion. Unique workflow improvements, including the use of microfluidics, allows previously lengthy assays to run in a fraction of the time – without sacrificing data quality. With Brevitest’s specialized cartridges and device, Brevitest can run a fully automated, quantitative assay in under 15 minutes.
This is a broadly applicable platform technology targeted towards markets with an unmet need for a sensitive, easy to use, point-of-care method to quantify molecules. Brevitest™ provides a novel solution for the traditional point-of-care clinical markets, estimated to be $25 billion worldwide. It also has the potential for use in diverse other areas where a low-cost, portable, quick, and user-friendly bioanalytical method is needed. We are working with co-developmental partners to develop and test the technology further with the goal of reaching a wide range of markets.
AACC’s Disruptive Technology Award (2018)
Small Business Innovation Research (SBIR) awards from the Department of Health and Human Services (2017)
National Institute on Drug Abuse (2016); the I-Corps at NIH™ award (2016)
The Texas New Ventures Competition prize (2015)
Goradia Innovation Prize (2014)
4 patents covering various aspects have been awarded.
BreviTest has won Small Business Innovation Research Grants (SBIR) from the National institute on Drug Abuse (2016) and Department of Health and Human Services (2017).
TEXAS NEW VENTURES PRIZE WINNER
In 2015, Brevitest was awarded a prize at the inaugural Texas New Ventures Competition (TNVC) sponsored by Texas A&M University. BreviTest was selected for a prize form a group of 91 eligible contestants and was recognized for its potential global impact in the medical field.
BreviTest (far left) was named a semi-finalist in the AACC’s first ever disruptive technology competition. Being a semi-finalist BreviTest was asked to present as a keynote technology at the 70th annual clinical lab expo in Chicago. This technology exposition is the largest in the world for clinical laboratory products and services, and included over 860 presenting companies.